electroCore to Participate at Canaccord Genuity 42nd Annual Growth Conference
electroCore to Participate at Canaccord Genuity 42nd Annual Growth Conference
ROCKAWAY, N.J., Aug. 05, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore's Chief Executive Officer, Dan Goldberger, will be presenting at the Canaccord Genuity 42nd Annual Growth Conference.
Canaccord Genuity 42nd Annual Growth Conference
Date: Thursday, August 11, 2022
Time: 8:30 AM EDT
Webcast: Canaccord Webcast
新泽西州罗克韦，2022年8月5日(环球网)--商用生物电子医药公司电芯公司(纳斯达克代码：ECOR)今天宣布，电芯公司首席执行官丹·戈德伯格将出席Canaccel Genuity第42届年度增长大会。
Canaccel Genuity第42届年度增长大会
日期：2022年8月11日(星期四)
时间：美国东部夏令时上午8：30
网络直播：Canaccel网络直播
Following the conferences, a webcast replay of the presentations will be available on the Investor section of the company's website, electroCore.
会议结束后，演示文稿的网络直播重播将在该公司网站的投资者栏目上播出，网址为ElectrCore。
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.
For more information, visit .
Investors:
Rich Cockrell
CG Capital
404-736-3838
ecor@cg.capital
关于电子核心公司
Electrcore，Inc.是一家商业阶段的生物电子药物公司，致力于通过其非侵入性迷走神经刺激治疗平台改善患者的预后，最初专注于神经科多种疾病的治疗。该公司目前的适应症是丛集性头痛和偏头痛的预防性治疗，偏头痛和发作性丛集性头痛的急性治疗，青少年偏头痛的急性和预防性治疗，以及成人的阵发性偏头痛和持续性偏头痛。
有关更多信息，请访问。
投资者：
里奇·科克雷尔
CG资本
404-736-3838
邮箱：ecor@cg.Capital